Analysis Biomolecular Interactions of Antibody with Various P[8] Molecules by BLI (CAT#: STEM-MB-0116-CJ)

Introduction

Vaccination is a cornerstone of public health for preventing illness and death due to common infectious diseases. Each NRRV antigen is a recombinant fusion-protein consisting of a truncated version of the rotavirus surface protein VP4 (known as VP8), genetically fused to the tetanus toxoid universal CD4+ T-cell epitope (P2). The three fusion-protein antigens derive from the VP8 component of three different RV serotypes, P[8], P[6], and P[4]. These sequence variants of P[8] and P[4] NRRV can be as a case study to demonstrate proof-of-concept for a two-stage formulation developability assessment workflow to rapidly assess formulation variables for recombinant vaccine antigens that could be applied to accelerate development of low-cost vaccine dosage forms targeted for use in low and middle income countries (LMICs).